Use of anti-IL-6 antibodies, such as clazakizumab, for desensitization of solid organ transplant recipients and / or for prevention, stabilization, or alleviation of antibody-mediated rejection (ABMR).

摘要

Prevents and stabilizes antibody-mediated rejection in patients undergoing solid organ transplantation, such as kidney, heart, liver, lung, pancreas, intestine, or any combination of the above. Provided is a novel therapeutic protocol for the use of anti-IL-6 antibodies, such as clazakizumab, for mitigation or inhibition. Waiting for allogeneic transplantation and / or undergoing a solid organ transplantation of a hypersensitized subject after allogeneic transplantation, such as kidney, heart, liver, lung, pancreas, intestine, skin, or any combination of the above Also provided are novel therapeutic protocols for the use of anti-IL-6 antibodies, such as clazakizumab, as part of a desensitization protocol to treat a patient who is to be treated. The aforementioned treatments can be performed in combination with one or more other immunosuppressive regimens or other desensitization procedures. [Selection diagram] Fig. 1